<DOC>
	<DOCNO>NCT03001986</DOCNO>
	<brief_summary>Enterovirus 71 ( EV71 ) , major pathogen cause hand-foot-and-mouth disease ( HFMD ) worldwide , member Human Enterovirus species A , family Picornaviridae . Its infection occasionally lead severe disease death , central nervous system ( CNS ) damage . Recently , except inactivated vaccine , several EV71 vaccine candidate evaluate animal final result clinical trial , attenuate vaccine , subunit vaccine . A formalin-inactivated EV71 vaccine ( Human Diploid cell , KMB-17 Cell ) finish phase I , II III clinical trial license SFDA China Dec. 3 , 2015 . Based result clinical trial , protective efficacy inactivate EV71 vaccine 97 % HFMD cause EV71 . The phase IV clinical trial carry July 2016 . The purpose phase IVb evaluate safety efficacy inactive EV71 vaccine large scale population Chinese child ( 6 71 month old ) Hubei Province , China .</brief_summary>
	<brief_title>The Phase IVb Inactivated Enterovirus 71 Vaccine ( Human Diploid Cell , KMB-17 ) Chinese Children</brief_title>
	<detailed_description>Enterovirus 71 ( EV71 ) , major pathogen cause hand-foot-and-mouth disease ( HFMD ) worldwide , member Human Enterovirus species A , family Picornaviridae . Its infection occasionally lead severe disease death , central nervous system ( CNS ) damage . Recently , except inactivated vaccine , several EV71 vaccine candidate evaluate animal final result clinical trial , attenuate vaccine , subunit vaccine . A formalin-inactivated EV71 vaccine ( Human Diploid cell , KMB-17 Cell ) finish phase I , II III clinical trial license SFDA China Dec. 3 , 2015 . Based result clinical trial , protective efficacy inactivate EV71 vaccine 97 % HFMD cause EV71 . The phase IV clinical trial carry July 2016 . The purpose phase IVb evaluate safety efficacy inactive EV71 vaccine large scale population Chinese child ( 6 71 month old ) . There three part phase IVb clinical trial perform . First , evaluate protect efficacy inactive EV71 vaccine large scale population Chinese child ( 6 71 month old ) , include HFMD , severe HFMD death . Second , evaluate safety inactive EV71 vaccine large scale population Chinese child ( 6 71 month old ) .</detailed_description>
	<mesh_term>Mouth Diseases</mesh_term>
	<mesh_term>Foot-and-Mouth Disease</mesh_term>
	<mesh_term>Hand , Foot Mouth Disease</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy subject ( 671 month old child ) establish medical history clinical examination The subject ' legal guardian must aware vaccine The subject ' legal guardian voluntarily participate study sign Informed Consent Form Subjects temperature ≤ 37.0 ℃ The subject ' legal guardian ability objective comply requirement protocol Persist 14month visit ( receive blood , stool ( specimen mean swab ) test accord program requirement immunogenicity observation group ) Allergy serious sideeffects vaccine ingredient vaccine Epilepsy , seizures , convulsion , neurological illness Congenital hereditary immunodeficiency Autoimmune disease Asthma , thyroidectomy , angioneurotic edema , diabetes cancer Asplenia , functional asplenia , circumstance lead asplenia splenectomy Clinical diagnosis coagulopathy ( clot factor deficiency , coagulation disorder , platelet abnormality ) , significant bruising blood clot disorder Acute illness acute exacerbation chronic disease last 7 day Any prior administration immunodepressant corticosteroid last 6 month Any prior administration blood product last 3 month Any prior administration liveattenuated vaccine last 15 day Any prior administration subunit inactivate vaccine last 7 day Fever vaccination , axillary temperature ﹥37.0 ℃ The laboratory test abnormality vaccination , include blood test ( hemoglobin , total white blood cell , WBC , platelet ) , blood biochemistry test ( ALT , total bilirubin , direct bilirubin , Cr , BUN ) urine test ( urine protein , urine sugar , blood cell ) , etc . Hypertension hypotension . Systolic blood pressure ﹥140 mmHg and/or diastolic blood pressure ﹥90 mmHg ; systolic blood pressure ﹤90 mmHg and/or diastolic blood pressure ﹤60 mmHg Any condition opinion investigator , may interfere evaluation study objective take part vaccine drug clinical trial last half year</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>71 Months</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>safety</keyword>
	<keyword>efficacy</keyword>
	<keyword>hand , foot mouth disease ( HFMD )</keyword>
</DOC>